Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer

Lenvatinib is approved for the first-line treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day, but its high toxicity often necessitates dose reductions and interruptions. To clarify the efficacy and safety of the reduced dose-initiation of lenv...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Yomi Nakashima, Ichiro Horie, Haruka Arimori, Mayu Ueda, Shinpei Nishikido, Yuta Nakamura, Keita Nakaji, Tetsuro Niri, Ayaka Sako, Ai Haraguchi, Toshiyuki Ikeoka, Satoru Akazawa, Akie Moriuchi, Misa Imaizumi, Toshiro Usa, Atsushi Kawakami
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	The Japan Endocrine Society 2025-12-01
סדרה:	Endocrine Journal
נושאים:	lenvatinib tyrosine kinase inhibitor radioiodine thyroid cancer
גישה מקוונת:	https://www.jstage.jst.go.jp/article/endocrj/72/12/72_EJ25-0251/_html/-char/en
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!